FINWIRES · TerminalLIVE
FINWIRES

Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment

By

(Updates with the stock move in the headline and the first two paragraphs.)

Gossamer Bio's (GOSS) shares surged more than 30% in Tuesday's pre-market activity after the company said it is proceeding toward a September new drug application submission for seralutinib as a potential treatment for patients with pulmonary arterial hypertension.

The plans follow a "productive" pre-application meeting with the U.S. Food and Drug Administration, the company said Monday, when shares closed almost 47% higher in regular trading.

Gossamer has also reacquired worldwide development and commercial rights to seralutinib from Chiesi, eliminating a previous 50/50 profit share deal and requiring Chiesi to make a one-time $5 million payment, it said.

Its shareholders have also approved proposals related to a convertible note exchange and authorized it to effect a reverse stock split, to take effect after Q3 2026, the company said.

The company also reported that cash, cash equivalents and marketable securities totaled approximately $57 million as of June 30.

Price: $0.26, Change: $+0.062, Percent Change: +30.39%

Related Articles

Wire

AuMEGA Metals Starts Inaugural Diamond Drilling at Canada Targets; Shares Fall 9%

AuMEGA Metals (ASX:AAM) started inaugural diamond drilling at targets at Isle aux Morts Granite and and the adjoining Cape Ray West area along the Cape Ray shear zone in Canada, according to a Tuesday Australian bourse filing.The drilling program is designed to test a series of structural, geochemical, and geophysical targets defined by integrating geological mapping, surface geochemistry, geophysics, and structural interpretation, per the filing.The company's shares fell nearly 9% in recent trading on Tuesday.

ASX:AAM
Wire

Brown & Brown Q2 Adjusted Earnings, Revenue Rise

Brown & Brown (BRO) reported Q2 adjusted earnings late Monday of $1.07 per diluted share, up from $1.03 a year earlier.Analysts polled by FactSet expected $1.08.Revenue in the three months ended June 30 rose to $1.68 billion from $1.29 billion a year earlier.Analysts expected $1.71 billion.The company's shares fell 1.8% in after-hours trading.

$BRO
Wire

Celestica Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Celestica (CLS) reported Q2 adjusted earnings late Monday of $2.54 per diluted share, up from $1.39 a year earlier.Analysts polled by FactSet expected $2.27.Revenue in the three months ended June 30 rose to $4.7 billion from $2.89 billion a year earlier.Analysts expected $4.33 billion.Celestica expects Q3 adjusted EPS of $2.88 to $3.08 on revenue of $5.25 to $5.55 billion.Analysts project EPS of $2.65 on revenue of $4.94 billion.The company boosted full-year guidance to adjusted EPS of $11.30 on revenue of $20.5 billion from the prior forecast of EPS of $10.15 on revenue of $19 billion.Analysts project EPS of $10.13 on revenue of $18.95 billion.Celestica shares rose 9.4% in after-hours trading.

$CLS